


IMMUNOLOGY



The development of new therapies for diseases of the immune system is a key priority for Boehringer Ingelheim. Our robust Immunology research and development pipeline is firmly anchored by a panel of external collaborations to deliver promising new compounds with the potential to transform the treatment of immune-mediated diseases.

Our Immunology partnering focus

We are seeking collaboration and in-licensing opportunities in the following areas:

- Crohn's disease: including specific approaches for fistulizing and refractory ileal Crohn's disease
- Ulcerative colitis
- Inflammatory skin diseases: including systemic sclerosis-scleroderma.

Within these areas, our specific research interests offer further opportunities for collaboration:

- Human genetics: identification of new therapeutic concepts and biomarkers
- Gut & skin epithelial barrier dysfunction: regulation of injury, inflammation and repair, including host-microbiome interactions
- Control of aberrant tissue remodeling and fibrosis
- Innate immune signaling pathways
- Immune regulatory receptors.

Contact:

Dr. David Blair

david.blair@boehringer-ingelheim.com